E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the efficacy of minocycline in the treatment of optic neuritis as measured by visual acuity |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The subject has to fulfil the following criteria at the time of randomization:
• The subject must give written informed consent prior to study activities
• Age between 18 and 50 years
• Has acute optic neuritis where the symptoms has lasted less than ten days and the visual acuity is less than 0.5 in either eye with best correction (standard criterion for conrticosteroid treatment). Subjects with optic neuritis as the first demyelinative event and subjects with previous diagnosis of MS with first optic neuritis are eligible
• Pre-study MRI shows at least one white matter lesion of more than >3mm in diameter.
|
|
E.4 | Principal exclusion criteria |
The subject must not be included if she/he fulfills any of the criteria at the time of randomization as mentioned below:
• Any condition which might cause similar symptoms as MS
• Has alcohol or drug abuse
• Has contraindications to MRI
• Has received treatment with steroids or ACTH later than 30 days before inclusion
• Has had a relapse within 30 days prior to inclusion into this study
• The patient has participated in any other clinical studies within 30 days prior to participating in the study
• Patient is pregnant or breast-feeding or planning pregnancy
- women in fertile age should have adequate contraception or be otherwise unlikely to become pregnant
• Has been treated with interferons, azathioprine, mitoxantrone or glatiramer acetate six months before entering the study
• Has elevated liver enzymes or has a known liver disease
- SGOT/SGPT over two times the upper normal limit
• Has known allergy to minocycline or other tetracyclines
• Previous optic neuritis
• Marked obesity (BMI>30) (risk of intracranial hypertension with tetracycline use)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• The primary endpoint is the visual acuity measured by using ETDRS chart at 6 months.
o Mean change in ETDRS points
o Number of patients with >15 points decrease in ETDRS points
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At Pre-Study / Baseline visit, 1 month visit and 6 month visit |
|
E.5.2 | Secondary end point(s) |
• The number of new or enlarging lesions in T2 weighted MRI compared to baseline MRI.
• The white matter lesion load (WMLL) in MRI compared to baseline.
• The use of high-dose glucocorticoid treatment for relapses (0-24 months).
• The number of patients without relapse at the end of study
• Mean change in visual evoked potentials (VEP) P100 response at 6 months.
Safety endpoints
• The occurrence of serious adverse events during the active treatment period
• The occurrence of adverse drug reactions during the active treatment period
• Changes in laboratory parameters evaluated throughout the study
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patients have routinely MRI in pre-study and study related MRI at 6 month visit |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |